A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 1.207,70 (+3,49%). A mediana é € 1.230,21 (+5,42%).

Comprar	33
Manter	9
Vender	3

Notícias Ir para o feed de notícias

Eli Lilly reaches new all-time high thanks to strong demand for tirzepatide products

Eli Lilly’s stock climbed to a new record, trading for the first time at $1,300 per share, driven by strong demand for the tirzepatide-based drugs Zepbound and Mounjaro. The two medicines generated about $15 billion in the second quarter; group revenues rose 48 percent overall to $23 billion. Investors are watching third-quarter figures expected on October 29, while Eli Lilly is simultaneously making acquisitions and expanding collaborations in AI and LNP areas, most recently with METiS TechBio. » Mais em deraktionaer.de
Eli Lilly receives EMA recommendation for weight-loss pill Foundayo

An EMA committee has recommended approval of Foundayo for weight control and for the treatment of type 2 diabetes in adults. The European Commission must still agree to the recommendation before Eli Lilly can market the drug in the EU. Foundayo would be, after Wegovy from Novo Nordisk, the second oral weight‑loss pill in the EU and increases competitive pressure on Novo, whose share price has fallen significantly from its peak. » Mais em manager-magazin.de
Eli Lilly ramps R&D and acquisitions to replace GLP-1 revenue before 2030s patent cliff

Eli Lilly, whose GLP-1 weight-loss and diabetes drugs generated 62% of trailing 12‑month revenue and helped push its market cap above $1 trillion, is spending heavily to diversify its pipeline before patents lapse in the 2030s. The company increased R&D to $13.3 billion in 2025 (and $7.3 billion in H1 2026) and has struck 31 deals this year, spending roughly $18 billion on acquisitions and licenses including Kelonia, Centessa and AtaiBeckley. Lilly is investing across oncology, neurology, sleep and psychedelics, and backing AI drug discovery with a $1 billion Nvidia partnership to seed next-generation blockbusters. CEO Dave Ricks says the moves aim to sustain growth rather than return capital if the GLP-1 franchise declines. » Mais em forbes.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2026, Eli Lilly & Co já distribuiu € 4,48 em dividendos. A última distribuição ocorreu em setembro.

Dados financeiros da empresa

No último trimestre, Eli Lilly & Co registou receitas de € 20,13 bi e um ganho líquido de € 6,22 bi

(EUR)	junho de 2026	YoY
Receitas	20,13 bi	52,50%
Ganho bruto	17,27 bi	55,24%
Ganho líquido	6,22 bi	29,44%
EBITDA	11,38 bi	78,91%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 1,07 tri
Número de ações	941,36 mi
Máximo/mínimo de 52 semanas	€ 1.168,94 - € 707,40
Rentabilidade de dividendos	0,51%
Dividendos TTM	€ 5,76
Beta	0,45
PER (PE Ratio)	42,51
PEG (PEG Ratio)	0,45
P/VC (PB Ratio)	33,47
P/V (PS Ratio)	15,02

Perfil da empresa

Eli Lilly and Company erforscht, entwickelt und vermarktet weltweit Humanarzneimittel. Es bietet Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R und Humulin U-500 für Diabetes; und Jardiance, Trajenta und Trulicity für Typ-2-Diabetes. Das Unternehmen bietet Alimta für nicht-kleinzelligen Lungenkrebs (NSCLC) und bösartiges Pleuramesotheliom; Cyramza für metastasierenden Magenkrebs, Adenokarzinom des gastroösophagealen Übergangs, metastasierenden NSCLC, metastasierenden kolorektalen Krebs und hepatozelluläres Karzinom; Erbitux für kolorektale Karzinome und verschiedene Kopf- und Halskrebsarten; Retevmo für metastasierten NSCLC, medullären Schilddrüsenkrebs und Schilddrüsenkrebs; Tyvyt für rezidivierte oder refraktäre klassische Hodgkin-Lymphome und nicht-squamösen NSCLC; und Verzenio für HR+, HER2- metastasierten Brustkrebs, knotenpositiven und frühen Brustkrebs. Es bietet Olumiant für rheumatoide Arthritis und Taltz für Plaque-Psoriasis, psoriatische Arthritis, ankylosierende Spondylitis und nicht-radiographische axiale Spondylarthritis. Das Unternehmen bietet Cymbalta für depressive Störungen, diabetische periphere neuropathische Schmerzen, generalisierte Angststörungen, Fibromyalgie und chronische Muskel-Skelett-Schmerzen; Emgality für Migräne-Prävention und episodische Cluster-Kopfschmerzen; und Zyprexa für Schizophrenie, bipolare Störung und bipolare Erhaltung. Seine Bamlanivimab und Etesevimab und Bebtelovimab für COVID-19; Cialis für erektile Dysfunktion und benigne Prostatahyperplasie; und Forteo für Osteoporose. Das Unternehmen arbeitet mit der Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc. und Foghorn Therapeutics Inc. zusammen. Eli Lilly and Company wurde 1876 gegründet und hat seinen Hauptsitz in Indianapolis, Indiana.

Nome	Eli Lilly & Co
CEO	David A. Ricks
Sede	Indianapolis, in EUA
Site	lilly.com
Setor	Cuidados de saúde
Indústria	Produtos farmacêuticos
Entrada em bolsa	01/06/1972
Colaboradores	50.000